ASCO16 Ribociclib & Abemaciclib Data

There is no excerpt because this is a protected post.

ASCO16 palbociclib (Ibrance©) Data

There is no excerpt because this is a protected post.

ASCO16 Avelumab, Durvalumab, and Tremelimumab

There is no excerpt because this is a protected post.

ASCO16 Atezolizumab (Tecentriq©) Data

There is no excerpt because this is a protected post.

ASCO16 Ipilimumab (Yervoy©) Data

There is no excerpt because this is a protected post.

ASCO16 Nivolumab (Opdivo©) Data

There is no excerpt because this is a protected post.

ASCO16 Pembrolizumab (Keytruda©) Data

There is no excerpt because this is a protected post.

ImmuneCheckpoint Inhibitors: New Endpoints on the Horizon

There is no excerpt because this is a protected post.

Immunotherapies: Which Cancer is Next?

https://www.washingtonpost.com/news/to-your-health/wp/2016/04/19/breakthrough-cancer-therapy-shows-growing-promise/ New immunotherapy drugs are showing significant and extended effectiveness against a broadening range of cancers, including rare and intractable tumors often caused by viruses. Researchers say these advances suggest the treatment approach is poised to become a critical part of the nation’s anti-cancer strategy. Read More…